{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:10:06Z","timestamp":1781680206718,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ygyno.2024.06.002","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T19:40:43Z","timestamp":1718048443000},"page":"13-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma"],"prefix":"10.1016","volume":"188","author":[{"given":"Annelise M.","family":"Wilhite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey T.","family":"Gibney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy","family":"Phung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino K.","family":"In","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dineo","family":"Khabele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt K.","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jubilee","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney P.","family":"Rocconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Y.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Scalici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2024.06.002_bb0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40257-019-00487-x","article-title":"Malignant melanoma of the vulva and vagina: a US population-based study of 1863 patients","volume":"21","author":"Wohlmuth","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0010","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.3390\/cancers14205123","article-title":"Cutaneous melanoma versus vulvovaginal melanoma\u2014risk factors, pathogenesis and comparison of immunotherapy efficacy","volume":"14","author":"Lorenz","year":"2022","journal-title":"Cancers"},{"issue":"166","key":"10.1016\/j.ygyno.2024.06.002_bb0015","first-page":"e7","article-title":"Primary genitourinary melanoma: epidemiology and disease-specific survival in a large population-based cohort","volume":"34","author":"Sanchez","year":"2016","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.ygyno.2024.06.002_bb0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with Nivolumab plus Ipilimumab or Nivolumab alone versus Ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0030","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0035","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0040","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2019.10.033","article-title":"Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: analysis from phase 2 and 3 clinical trials","volume":"125","author":"Hauschild","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.06.002_bb0045","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","article-title":"Long-term outcomes in patients with BRAF V600\u2013mutant metastatic melanoma who received Dabrafenib combined with Trametinib","volume":"36","author":"Long","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0050","doi-asserted-by":"crossref","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2024.06.002_bb0055","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus Ipilimumab in lung Cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0060","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0065","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.22.01599","article-title":"Seven-year follow-up of the phase III KEYNOTE-006 study: Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"41","author":"Robert","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0070","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.annonc.2021.09.016","article-title":"Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the friends of Cancer research TMB harmonization project","volume":"32","author":"Vega","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0075","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/cam4.1372","article-title":"Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients","volume":"7","author":"Vanderwalde","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0080","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13073-020-00787-6","article-title":"Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types","volume":"12","author":"Bao","year":"2020","journal-title":"Genome Med."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0085","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13293-020-00301-y","article-title":"The impact of sex and gender on immunotherapy outcomes","volume":"11","author":"Klein","year":"2020","journal-title":"Biol. Sex Differ."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0095","doi-asserted-by":"crossref","first-page":"11942","DOI":"10.3390\/ijms222111942","article-title":"Gender differences and immunotherapy outcome in advanced lung Cancer","volume":"22","author":"Vaval\u00e0","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0100","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of Nivolumab alone or in combination with Ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D\u2019Angelo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0105","series-title":"CheckMate 067: Long-term outcomes in patients with mucosal melanoma. Journal of Clinical Oncology","author":"Shoushtari","year":"2020"},{"key":"10.1016\/j.ygyno.2024.06.002_bb0110","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of Pembrolizumab in advanced, programmed death ligand 1\u2013positive cervical Cancer: results from the phase Ib KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0115","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0120","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0125","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1002\/cam4.3789","article-title":"Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade","volume":"10","author":"Buchbinder","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0130","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/cncr.30473","article-title":"Vulvar and vaginal melanoma: a unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma: molecular study of vulvovaginal melanoma","volume":"123","author":"Hou","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2024.06.002_bb0135","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejca.2015.10.069","article-title":"Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French sarcoma group","volume":"52","author":"Patrikidou","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.06.002_bb0140","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaad.2014.03.031","article-title":"Update on primary mucosal melanoma","volume":"71","author":"Tacastacas","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"issue":"8","key":"10.1016\/j.ygyno.2024.06.002_bb0145","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1158\/2159-8290.CD-20-0555","article-title":"Splicing patterns in SF3B1 -mutated uveal melanoma generate shared immunogenic tumor-specific Neoepitopes","volume":"11","author":"Bigot","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ygyno.2024.06.002_bb0150","doi-asserted-by":"crossref","first-page":"9535","DOI":"10.1200\/JCO.2021.39.15_suppl.9535","article-title":"Clinical characteristics of SF3B1 mutant (Mut) uveal melanoma (UM) and response to immune checkpoint inhibition (ICI)","volume":"39","author":"Grimes","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.06.002_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.524700","article-title":"Poor lymphocyte infiltration to primary tumors in Acral lentiginous melanoma and mucosal melanoma compared to cutaneous melanoma","volume":"10","author":"Nakamura","year":"2020","journal-title":"Front. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824002762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824002762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T21:23:18Z","timestamp":1738704198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824002762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":31,"alternative-id":["S0090825824002762"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.06.002","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}